ReviewDisease markers2016
Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes.
Review in Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Article
- Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.International journal of molecular sciences · 2025Article
- Protocols for Extraction of miRNA from Extracellular Vesicles of Lyophilized Human Saliva Samples.International journal of molecular sciences · 2025Article
- Repurposing ProTAME for Bladder Cancer: A Combined Therapeutic Approach Targeting Cell Migration and MMP Regulation.Biology · 2025Article
- Article
- Molecular Biomarkers of Bladder Cancer: A Mini-Review.Physiological research · 2023Review
- miR-145 as a Potential Biomarker and Therapeutic Target in Patients with Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Article
- Predicting the effects of rare genetic variants on oncogenic signaling pathways: A computational analysis of HRAS protein function.Frontiers in chemistry · 2023Article
- Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis.Frontiers in bioengineering and biotechnology · 2023Article
- Detection of Urinary Molecular Marker Test in Urothelial Cell Carcinoma: A Review of Methods and Accuracy.Diagnostics (Basel, Switzerland) · 2022Review
- Downregulation of BLM RecQ helicase inhibits proliferation, promotes the apoptosis and enhances the sensitivity of bladder cancer cells to cisplatin.Molecular medicine reports · 2022Article
- Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.World journal of urology · 2022Article
- A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.Saudi journal of biological sciences · 2022Review
- The role of Exosomal miRNAs in cancer.Journal of translational medicine · 2022Review
- Review
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression.Clinical and translational medicine · 2021Article
- Exosomal miR-590-5p in Serum as a Biomarker for the Diagnosis and Prognosis of Gastric Cancer.Frontiers in molecular biosciences · 2021Article
- A potential prognostic model based on miRNA expression profile in The Cancer Genome Atlas for bladder cancer patients.Journal of biological research (Thessalonike, Greece) · 2020Article
- Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.Journal of nanobiotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many clinical and molecular markers for predicting outcomes in bladder cancer (BC) have been reported, their application in clinical practice remains unclear. Bladder carcinogenesis has two distinct molecular pathways that direct the development of BC. FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC. However, no tissue-based gene markers confirmed by prospective large-scale trials in BC have been used in clinical practice. Micro-RNA analyses of BC tissue revealed that miR-145 and miR-29c* function as tumor suppressors, whereas miR-183 and miR-17-5p function as oncogenic miRNAs. In liquid biopsy, circulating tumor cells (CTC), exosomes, or cell-free RNA is extracted from the peripheral blood samples of cancer patients to analyze cancer prognosis. It was reported that detection of CTC was associated with poor prognostic factors. However, application of liquid biopsy in BC treatment is yet to be explored. Although several cell-free RNAs, such as miR-497 in plasma or miR-214 in urine, could be promising novel circulating biomarkers, they are used only for diagnosing BC as the case that now stands. Here, we discuss the application of novel biomarkers in evaluating and measuring BC outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.